Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-016002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-03 | 2023-03-01 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | S - Sale | $8.54 | -1,436 | 175.4K | -0.8% | -$12.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | S | D | 1,436 | $8.54 | 175,371 | D | — | — | (F2) Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |